Latest Breaking News On - Sangeeta bhorade - Page 1 : comparemela.com

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

AUSTIN, Texas, April 11, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics .

Natera Announces Data from the ProActive Study that Supports Prospera Kidney as an Early Indicator of Transplant Rejection

05.06.2023 - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several . Seite 1

Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients